Degradation Kinetics and Characterization of Canagliflozin Under Solution Stress by LC and LC-MS/MS Method

ABSTRACT

Objectives: Using the RP-HPLC method, this work investigates the degradation behavior of canagliflozin and its commercial formulation under ICH-recommended stress conditions. It also validates the suggested method and analyzes degraded samples’ solution state using LC-MS/MS. Materials and Methods:The solution-state degradation study of canagliflozin in tablet dosage form was performed using the Shimadzu-HPLC series 1100. The acetonitrile (50:50) v/v mobile phase, ammonium acetate buffer pH 4.5 and an ACE BDS C18 column (150×2.5 mm, 4.6 mm) were utilized in the analysis. The wavelength chosen for the study was 291 nm, at which the drug displayed a strong peak and methanol was employed as diluent. An Agilent 1110-LC system was connected to a Shimadzu LC-MS/MS-8040 outfitted with a PDA-SPD M20A and an Electrospray Ionization (ESI) source interface for LC-MS analysis. Canagliflozin was exposed for 180 min at 50ºC in solution state degradation experiments using acidic, basic, neutral and peroxide conditions. Results: HPLC was used to detect the degradation products and HPLC-Mass Spectroscopy (LC/ MS/MS) was used to characterize them. Major peaks at 293.0, 281.70, 224.90, 221.50, 180.90, 145.90 and 104.90 were visible in the LC-MS data. It was found that the canagliflozin formulation which was marketed was labile under stress conditions which included neutral, oxidative, alkaline and acidic. Conclusion:The deteriorated samples were analyzed using the LC-MS/MS technique and potential structures were allocated in accordance with the drug’s known reactivity.

KEYWORDS

• Canagliflozin
• Degradation
• Kinetics
• LC-MS/MS
• Stability

Showing references and in-text citations exactly as published.

• DOI10.5530/ijper.20266836Copy

RELATED ARTICLES

Matched on section and article type within this issue of IJPER.

• Article · VOLUME 60, ISSUE 1SThe Role of EPAC in the Pathogenesis of Cardiovascular Complications: A ReviewNandini Dubey, Vishal Kumar Vishwakarma, Aanchal Verma, Ahsas Goyal, Harlokesh Narayan Yadav · pp. s1–s10Research ArticleSame type: Article
• Article · VOLUME 60, ISSUE 1SGlobal Comparison of Gene and Cell Therapy Regulations: A Cross-Regional Analysis of FDA, EMA, TGA, CSFDA, DCGI, PMDA, IFDA and MFDSSeyed Heidar Mohammadi, Gholamhossein Sadeghian, Hoseein Shomali, Mohamadreza Abedi, Behrooz Jannat, Faham Khamesipour · pp. s18–s32Research ArticleSame type: Article
• Article · VOLUME 60, ISSUE 1SReview on Exploring the Combination Effect of Aldosterone along with Plasma Renin with Melatonin and Hydro-Cortisol in Diurnal RhythmMainak Pal, Masud Sk, Saheli Mandal, Dipanjan Mandal · pp. s33–s41Research ArticleSame type: Article
• Article · VOLUME 60, ISSUE 1SRegulatory Pathway for Genotoxic Impurities in Europe, US, Canada, India, Australia and UKKavyashree Kadehalli Ramegowda, Sangita Mishra, Venkatesh Madhugiri Prakash · pp. s42–s51Research ArticleSame type: Article